

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2026**

**Commission File Number: 001-41115**

**GENENTA SCIENCE S.P.A.**

(Translation of registrant's name into English)

**Via dell'Annunciata 31**

**20121 Milan, Italy**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

This report on Form 6-K, including Exhibit 99.1, is incorporated by reference into the registrant's registration statement on Form S-8 (File No. 333-278392).

---

---

## Other Events

### *Genenta's Ordinary and Extraordinary Shareholders' Meeting*

On May 30, 2026, Genenta Science S.p.A. (the "Company") issued a notice (the "Notice") regarding its Ordinary and Extraordinary Shareholders' Meeting (the "Meeting") to be held, pursuant to Article 9.5 of the Company's bylaws, exclusively by teleconference, on June 29, 2026 at 5:00 p.m. (Central European Summer Time), on first call, and, if necessary, on June 30, 2026 at 5:30 p.m. (Central European Summer Time), on second call.

During the ordinary session of the Meeting, the Company's shareholders will be asked to approve, among other matters, (1) the Company's financial statements for the fiscal year ended December 31, 2025, (2) appointment of the Board of Directors of the Company (the "Board") (including determination of related compensation), and (3) the authorization to purchase and dispose of treasury shares. In connection with item (2), two alternative slates of candidates for the Board have been submitted by shareholders pursuant to the slate voting mechanism provided for under the Company's bylaws.

During the extraordinary session of the Meeting, the Company's shareholders will be asked to approve, among other matters, (1) a proposed amendment to the Company's bylaws to change the Company's corporate name from Genenta Science S.p.A. to Saentra Forge S.p.A., (2) a proposed delegation to the Board to increase the share capital and/or to issue convertible bonds, and (3) a proposed reverse stock split of the Company's ordinary shares within a range to be approved by the shareholders. Following shareholder approval of the reverse stock split, the Board will have discretion to determine the exact ratio and whether to effectuate the reverse stock split, based on the Board's ascertainment of the Company's failure to achieve stable compliance with Nasdaq listing requirements.

A copy of the Notice is furnished as Exhibit 99.1 to this Report on Form 6-K and is incorporated herein by reference. Additionally, the Notice and other related materials and information related to the upcoming Meeting can be found on the Company's website at [www.genenta.com](http://www.genenta.com) under the *News & Events* tab, under Ordinary and Extraordinary Shareholders' Meeting, June 2026 (English or Italian Version).

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GENENTA SCIENCE S.P.A.**

By: /s/ Pierluigi Paracchi

Name: Pierluigi Paracchi

Title: Chief Executive Officer

Dated: June 17, 2026

---

**Exhibits.**

Exhibit No.	Description
99.1	<a href="#">Notice of Call of Ordinary and Extraordinary Shareholders' Meeting dated May 30, 2026.</a>

---



NOTICE OF CALL OF ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING

Please note that the **Ordinary and Extraordinary Shareholders' Meeting** of **Genenta Science S.p.A.** has been convened, in accordance with Article 9.5 of the Bylaws, exclusively by teleconference, on June 29, 2026 at 5:00 p.m., on first call, and, if necessary, on June 30, 2026, at 5:30 p.m. and with the same manner, on second call, to resolve on the following

**AGENDA**

**Ordinary session**

1. Approval of the financial statements for the fiscal year ended December 31, 2025; inherent and consequent resolutions.
2. Appointment of the Board of Directors; inherent and consequent resolutions.
  - 2.1 Determination of the number of Board Members;
  - 2.2 Determination of term of office;
  - 2.3 Appointment of the Board members;
  - 2.4 Appointment of the Chairman of the Board of Directors;
  - 2.5 Determination of the related compensation.
3. Authorization to purchase and dispose of treasury shares pursuant to Articles 2357 and 2357-ter of the Italian Civil Code; inherent and consequent resolutions.

**Extraordinary session**

1. Amendment to Article 1 of the Company's by-laws to change the corporate name from Genenta Science S.p.A. to Saentra Forge S.p.A.; inherent and consequent resolutions.
2. Grant to the Board of Directors of a delegation pursuant to Article 2443 and Article 2420-ter of the Italian Civil Code to increase the share capital against payment and/or to issue convertible bonds, in one or more tranches and on a divisible basis, up to a maximum amount of Euro 300,000,000, including any share premium, through the issuance of up to no. 120,000,000 new ordinary shares with no par value and with regular dividend entitlement, also with exclusion of pre-emptive rights or on a gratuitous basis, also pursuant to Article 2441, paragraphs 4 and/or 5 and/or 8, of the Italian Civil Code, for a period of five years from the date of the resolution; consequent amendment to Article 6 of the Company's by-laws; inherent and consequent resolutions.
3. Reverse stock split; consequent amendment to Article 6 of the Company's by-laws; inherent and consequent resolutions.

\* \* \*

For information on eligibility to participate in the Shareholders' Meeting, the manner of participation, as well



as the exercise of voting rights, please refer to the relevant documentation available, together with this notice, on the Company's website at [www.genenta.com](http://www.genenta.com), as well as at the registered office in Milan, via dell'Annunciata, 31. The documentation relating to the items on the agenda will be made available on the aforementioned website as well as at the registered office within the terms required by law.

Milan, May 30, 2026

The Chairman of the Board of Directors

**Pierluigi Paracchi**

